Karamvir Yadav, Medical Oncologist in Jaipur, India, shared posts on X:
“Ultra-low-dose nivolumab (20 mg q2w) shows significant OS benefit vs chemo in refractory solid tumors (HR 0.80).
- Comparable tumor control
- Longer DOR
- Better QoL
- Lower toxicity
A potential game-changer for LMIC access.”
Other articles featuring Karamvir Yadav on OncoDaily.